Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.98
IPCI's Cash to Debt is ranked lower than
72% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. IPCI: 1.98 )
Ranked among companies with meaningful Cash to Debt only.
IPCI' s 10-Year Cash to Debt Range
Min: 0.35  Med: 10000.00 Max: No Debt
Current: 1.98
Equity to Asset 0.44
IPCI's Equity to Asset is ranked lower than
75% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IPCI: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
IPCI' s 10-Year Equity to Asset Range
Min: -1.36  Med: 0.95 Max: 1
Current: 0.44
-1.36
1
F-Score: 2
Z-Score: 2.17
M-Score: -3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -97.69
IPCI's Operating margin (%) is ranked lower than
54% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. IPCI: -97.69 )
Ranked among companies with meaningful Operating margin (%) only.
IPCI' s 10-Year Operating margin (%) Range
Min: -1046100  Med: -4813.51 Max: -40.29
Current: -97.69
-1046100
-40.29
Net-margin (%) -105.67
IPCI's Net-margin (%) is ranked lower than
56% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. IPCI: -105.67 )
Ranked among companies with meaningful Net-margin (%) only.
IPCI' s 10-Year Net-margin (%) Range
Min: -914800  Med: -4913.51 Max: -43.97
Current: -105.67
-914800
-43.97
ROE (%) -109.84
IPCI's ROE (%) is ranked lower than
83% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. IPCI: -109.84 )
Ranked among companies with meaningful ROE (%) only.
IPCI' s 10-Year ROE (%) Range
Min: -233.45  Med: -93.40 Max: -34.03
Current: -109.84
-233.45
-34.03
ROA (%) -64.77
IPCI's ROA (%) is ranked lower than
77% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. IPCI: -64.77 )
Ranked among companies with meaningful ROA (%) only.
IPCI' s 10-Year ROA (%) Range
Min: -341.48  Med: -86.03 Max: -32.23
Current: -64.77
-341.48
-32.23
ROC (Joel Greenblatt) (%) -307.91
IPCI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. IPCI: -307.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9384  Med: -2884.96 Max: -235.63
Current: -307.91
-9384
-235.63
Revenue Growth (3Y)(%) 142.90
IPCI's Revenue Growth (3Y)(%) is ranked higher than
97% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. IPCI: 142.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -50.00 Max: 142.9
Current: 142.9
0
142.9
EBITDA Growth (3Y)(%) -33.90
IPCI's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. IPCI: -33.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -10.90 Max: 44.9
Current: -33.9
0
44.9
EPS Growth (3Y)(%) -17.10
IPCI's EPS Growth (3Y)(%) is ranked lower than
62% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. IPCI: -17.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPCI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 3.50 Max: 63.9
Current: -17.1
0
63.9
» IPCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 42.37
IPCI's Forward P/E is ranked lower than
73% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. IPCI: 42.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 28.64
IPCI's P/B is ranked lower than
95% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. IPCI: 28.64 )
Ranked among companies with meaningful P/B only.
IPCI' s 10-Year P/B Range
Min: 6.88  Med: 13.36 Max: 496
Current: 28.64
6.88
496
P/S 17.18
IPCI's P/S is ranked lower than
60% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. IPCI: 17.18 )
Ranked among companies with meaningful P/S only.
IPCI' s 10-Year P/S Range
Min: 6.07  Med: 29.22 Max: 317
Current: 17.18
6.07
317
EV-to-EBIT -17.34
IPCI's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. IPCI: -17.34 )
Ranked among companies with meaningful EV-to-EBIT only.
IPCI' s 10-Year EV-to-EBIT Range
Min: -56.2  Med: -6.05 Max: -2.9
Current: -17.34
-56.2
-2.9
Current Ratio 1.22
IPCI's Current Ratio is ranked lower than
85% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. IPCI: 1.22 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s 10-Year Current Ratio Range
Min: 0.37  Med: 5.40 Max: 94.99
Current: 1.22
0.37
94.99
Quick Ratio 1.22
IPCI's Quick Ratio is ranked lower than
80% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. IPCI: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s 10-Year Quick Ratio Range
Min: 0.37  Med: 5.40 Max: 94.99
Current: 1.22
0.37
94.99
Days Sales Outstanding 54.40
IPCI's Days Sales Outstanding is ranked higher than
56% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. IPCI: 54.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s 10-Year Days Sales Outstanding Range
Min: 0.5  Med: 10.23 Max: 352.81
Current: 54.4
0.5
352.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 66.80
IPCI's Price/Net Cash is ranked lower than
251% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. IPCI: 66.80 )
Ranked among companies with meaningful Price/Net Cash only.
IPCI' s 10-Year Price/Net Cash Range
Min: 0.02  Med: 0.63 Max: 89
Current: 66.8
0.02
89
Price/Net Current Asset Value 27.83
IPCI's Price/Net Current Asset Value is ranked lower than
211% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. IPCI: 27.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IPCI' s 10-Year Price/Net Current Asset Value Range
Min: 0.02  Med: 0.63 Max: 100.25
Current: 27.83
0.02
100.25
Price/Tangible Book 18.56
IPCI's Price/Tangible Book is ranked lower than
92% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. IPCI: 18.56 )
Ranked among companies with meaningful Price/Tangible Book only.
IPCI' s 10-Year Price/Tangible Book Range
Min: 0.02  Med: 0.58 Max: 258
Current: 18.56
0.02
258
Price/Median PS Value 0.34
IPCI's Price/Median PS Value is ranked lower than
213% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. IPCI: 0.34 )
Ranked among companies with meaningful Price/Median PS Value only.
IPCI' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 3.41 Max: 151.72
Current: 0.34
0.22
151.72
Earnings Yield (Greenblatt) (%) -5.79
IPCI's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IPCI: -5.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPCI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -671.7  Med: 0.00 Max: 0
Current: -5.79
-671.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I.Canada, I4A.Germany,
IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, they have developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics Announces Second Quarter 2015 Results Jul 13 2015
Intellipharmaceutics reports 2Q loss Jul 13 2015
Intellipharmaceutics reports 2Q loss Jul 13 2015
Intellipharmaceutics Announces Second Quarter 2015 Results Jul 13 2015
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R) Jul 08 2015
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R) Jul 08 2015
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R) Jun 18 2015
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R) Jun 18 2015
Why IntelliPharmaCeutics Just Had A Big Tuesday May 26 2015
Intellipharmaceuticals (IPCI) Stock Rises on Rexista Fast Track Designation May 26 2015
IntelliPharmaCeutics International (IPCI) in Focus: Stock Jumps 5.4% - Tale of the Tape May 26 2015
FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) Oxycodone XR Incorporating... May 26 2015
FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) Oxycodone XR Incorporating... May 26 2015
Intellipharmaceutics Announces Agreement to Acquire Real Property that Houses its Manufacturing, R&D... May 25 2015
Intellipharmaceutics Announces Agreement to Acquire Real Property that Houses its Manufacturing, R&D... May 25 2015
IntelliPharmaCeutics Int'l. (IPCI) Stock Spikes on Positive Non-Abusive Oxycontin Development May 21 2015
Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the... May 21 2015
Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the... May 21 2015
IntelliPharmaCeutics International (IPCI) Jumps: Adds 7.8% - Tale of the Tape Apr 28 2015
Intellipharmaceutics Reports Director Election Results Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK